The MCED paradox sits at the intersection of a single blood test and two opposite verdicts: an FDA advisory panel endorsed it 7 to 2 the same week the NHS-Galleri trial — 140,000 participants — found it did not meet its primary endpoint. Both conclusions were defensible. Neither was wrong.
The Week a Trial Failed and a Panel Cheered
Somewhere in a meeting room, a regulator reads the same number as a clinician and reaches the opposite conclusion. That is not spin, not politics, not a failure of communication. Sometimes it is just the data being genuinely difficult. In the same week in September 2026, the world received two verdicts on the same blood test, and they pointed in opposite directions.
The NHS-Galleri trial, the largest screening study of its kind, enrolled 140,000 asymptomatic people across England. The question it was built to answer was clean and serious: does this test actually reduce the number of cancers found at Stage III and IV combined, the stages where survival curves turn grim? The answer, when it arrived, was no. The trial failed its primary endpoint. NHS England drew the only defensible conclusion available to a public health body facing that result: the Galleri test is not ready for routine national rollout.
Across the Atlantic, a U.S. FDA advisory panel looked at the evidence and voted 7 to 2 that the benefits of the same test outweigh its risks. Not unanimous, not without reservations, but a clear majority. The panel noted concerns about overdiagnosis, then endorsed the test anyway.
Here is the strange part. Both bodies were right to do what they did, given their different mandates, their different risk tolerances, and the specific sliver of data each was weighing. The contradiction is not a reporting error. It is not confusion. It is the story itself, a single blood test sitting at the precise point where promising and proven have not yet become the same thing, and the institutions we built to protect us are working out, in real time, what that gap actually costs.
What a Teaspoon of Blood Can — and Cannot — Tell You
Every cell in your body, when it dies, releases fragments of its DNA into the bloodstream. Most of that circulating debris is unremarkable. But tumour cells shed their own fragments too, and a liquid biopsy tries to fish those out, identify their methylation patterns, and name the cancer before it announces itself through symptoms. It is, in concept, elegant.
The biology, however, is not cooperative. An early-stage tumour is small, its contribution to the bloodstream proportionally tiny, and the signal it casts is barely distinguishable from background noise. Sensitivity for Stage I cancers sits around 17% across current blood tests. By Stage IV, when the tumour has had years to grow and spread, sensitivity climbs to roughly 90% — which is almost the opposite of what a screening programme needs.
Some cancers compound the problem structurally. Prostate and kidney tumours shed minimal circulating tumour DNA regardless of how large they grow, making them partly invisible to a blood-based test at any stage. The test is, in other words, better at finding the cancers that are already loudly present, and quieter about the ones that haven't yet started shouting.
There is also a naming collision worth flagging. MCED is used in oncology for multi-cancer early detection, but the same acronym appears in vascular biology, where it describes massively calcified endosomal death, a distinct cell-death mechanism observed in the endothelial cells of arteries. The two have nothing to do with each other. It matters only because literature searches produce confusing results, and confusion in medicine has a way of spreading.
Understanding where the biology is hard is the prerequisite for understanding where the numbers go wrong.
The Detection Gradient: Cancer Hides Best When You Most Need to Find It
Think of the test's sensitivity as a dial that turns the wrong way. For Stage IV cancer, when the disease has already spread through the body and the bloodstream is thick with shed DNA fragments, the Galleri test catches roughly 90% of cases. For Stage I, when the tumour is small, contained, and most treatable, that number drops to about 17%. The biology is not being cruel on purpose; early tumours simply shed very little cell-free DNA, too little for even a careful molecular search to reliably find.
That gradient is the structural problem at the heart of the MCED debate. The test is sharpest exactly where you need it least and bluntest exactly where you need it most. A screening tool that excels at Stage IV is a little like a smoke detector that trips reliably only after the ceiling is already burning.
The specificity number looks reassuring at first glance: 99.5%. In a room of 200 healthy people, roughly one gets a false alarm. But run that test across millions of asymptomatic adults and the arithmetic shifts uncomfortably fast. One in 200 is not a small number when the denominator is a national health system.
Earlier GRAIL trials ran into technical and methodological challenges that kept the picture blurry for years. Those earlier limitations partly explain why the NHS-Galleri trial was designed so carefully, and why its results, when they finally came, landed so hard. The pipeline had been built on provisional data.
Taken together, these numbers are not a verdict against the test. They are a description of what the test actually is, which turns out to be something considerably more complicated than a blood draw and a yes or no.
The test is sharpest exactly where you need it least and bluntest exactly where you need it most.
The MCED Paradox, Precisely Stated
Picture two columns on a whiteboard, drawn in marker the morning the NHS-Galleri trial results came in. On the left: Stage IV cancers, the kind already spreading when found. The trial caught fewer of those. Fourteen percent fewer in the first round, rising to twenty-six percent fewer by the third year of screening. That is a real number. In a disease that kills by metastasis, finding it before it fully escapes is exactly what you want.
Now look at the right column. Stage III and IV cancers, combined. That was the agreed measure of success, written into the trial protocol before a single blood tube was drawn. The reduction there did not reach statistical significance. The primary endpoint was not met.
Two columns. One goes down. The other does not move enough to count.
This is the paradox in its technical form, and it rewards a moment of honest staring. Stage shift is real: the test is genuinely finding some cancers earlier. But whether finding them earlier prevents the worst outcomes is a different question entirely, and that question remains open. Professor Peter Sasieni put it plainly: the test shifts detection to earlier stages, and whether that shift ultimately reduces population-level mortality is still unclear.
Then there is the positive predictive value. When someone receives a cancer signal from this test, the probability that a cancer is actually present sits between fifty-two and sixty percent. Flip it over: roughly one in every two positive signals does not represent cancer. The test's specificity is impressively high at 99.5 percent, which sounds like precision. But precision and predictive value are not the same thing, and conflating them is how confusion spreads.
The subset succeeded. The primary endpoint failed. Both are true simultaneously. That is not a contradiction to be explained away; it is the exact shape of the problem everyone now has to solve.
The Hidden Invoice: False Positives, Life Insurance, and the $1,000 Question
Before you take the test, one piece of clinical guidance stands out like a fire exit sign you hope never to use: it is advisable to obtain life insurance first. Not after. Before. That single sentence from the AANP clinical tool tells you almost everything about the hidden costs the brochure does not mention.
A positive result, even a false one, may follow you. Because the Positive Predictive Value sits between 52% and 60%, roughly one in two people who receive a "cancer signal detected" result do not actually have cancer. But the signal is already in the record. Life insurers are not required to ignore it.
Then comes what oncologists call the diagnostic odyssey. Biopsies. CT scans. Repeat blood draws. Months of appointments to locate a tumor that may not exist. The emotional and financial toll of that search is real, even when the ending is relief.
And this is where the comparison to other screening programs sharpens. A mammogram costs around $100 and is covered. A colonoscopy runs higher but is routinely reimbursed. One Galleri test, today, costs $500 to $1,000 out of pocket. Medicare coverage begins in 2029 under the Nancy Gardner Sewell Act, but that is three years away for a test an FDA panel endorsed last week.
The people most likely to benefit from catching cancer early — those without a family doctor watching them closely, those who skip symptoms because sick days are not free — are also the people least likely to spend $1,000 on a blood draw. Early detection is becoming a luxury good. That is a strange outcome for a technology built to save lives.
2029, and the Questions Nobody Has Answered Yet
The Nancy Gardner Sewell Medicare MCED Screening Coverage Act schedules Medicare coverage for multi-cancer early detection tests beginning in 2029. That date is fixed in law. What happens around it remains almost entirely open.
Start with the number that matters most and is still missing: nobody has calculated what a nationwide screening programme costs once you add the diagnostic odysseys. The 0.5% false-positive rate sounds reassuring until you multiply it across millions of screened adults. Each false alarm pulls a person through CT scans, biopsies, specialist appointments. The aggregate bill for those cascading investigations has not been totaled. The systemic cost of the workup, not the test, is the uncalculated variable in every budget model.
Then there is the mortality question. The NHS-Galleri trial showed a 14% reduction in Stage IV cancers, rising to 26% by year three. That is a real signal. Whether it eventually bends the overall mortality curve is a different and harder question, one the trial was not designed to answer definitively. Professor Peter Sasieni said it plainly: it remains unclear whether the stage shift will reduce population-level mortality. Finding cancer earlier is not the same thing as saving more lives, especially when Stage IV, by definition, means the disease has already spread systemically.
Full non-provisional FDA approval for population-wide use has no confirmed timeline. The 7-2 advisory panel vote endorsed benefits outweighing risks; it did not end the regulatory story.
The MCED paradox has not resolved itself. Both supporters and critics of multi-cancer early detection screening share one honest position: the evidence is not yet complete. The test exists. The law has a start date. The answer to the question that actually matters — does this keep people alive longer — is still being written.
